Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (NYSE: LH), a leading provider of innovative laboratory services, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's executive management team will engage in a fireside chat on Tuesday, September 9, at 7:45 am ET.
Investors and interested parties can access a live audio webcast of the presentation through Labcorp's investor relations website at ir.Labcorp.com. The presentation will also be archived for future replay.
Labcorp (NYSE:LH) has launched the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood test for Alzheimer's disease diagnosis. This groundbreaking test demonstrates 92% positive predictive value and 97% negative predictive value in clinical studies.
The blood-based diagnostic test provides comparable results to traditional methods like CSF testing and PET scans, but through a simpler, more affordable, and less invasive blood draw. Available nationwide through Labcorp's 2,200+ Patient Service Centers, the test is designed for adults 50 and older showing cognitive decline symptoms in specialized care settings.
Labcorp (NYSE: LH) has launched Test Finder, a pioneering generative AI tool developed in collaboration with Amazon Web Services (AWS). The tool aims to streamline laboratory test selection for healthcare providers by allowing them to input queries in plain language and receive curated test recommendations.
Test Finder, built using Amazon Bedrock and large language model technology, provides access to thousands of lab tests across multiple therapeutic areas. The tool addresses a significant healthcare challenge, as laboratory testing influences nearly 70% of clinical decisions, while physicians spend over three hours daily on documentation and test ordering. According to an AMA survey, 57% of physicians view administrative automation through AI as healthcare's greatest AI opportunity.
Labcorp (NYSE: LH) has achieved IVDR CE-marking for its PGDx elio tissue complete test in the European Union, making it the first and only test of its kind approved for comprehensive solid tumor profiling under new EU regulations. The test, which already has FDA clearance in the US, will help diagnose and treat approximately 2.7 million people diagnosed with cancer annually in the EU.
The in vitro diagnostic assay can analyze multiple biomarkers simultaneously, even with limited tissue samples, enabling faster and more effective patient management plans. The test will be available through Labcorp's central laboratory in Geneva, Switzerland, supporting both biopharma partners and investigational use in global clinical trials.
Labcorp (NYSE: LH) reported strong Q2 2025 results with revenue of $3.53 billion, up 9.5% from Q2 2024. The company achieved diluted EPS of $2.84 and adjusted EPS of $4.35, marking a 10.4% increase year-over-year.
Based on strong performance, Labcorp raised its full-year 2025 guidance, with revenue growth now expected at 7.5% to 8.6%, adjusted EPS range of $16.05 to $16.50, and free cash flow projected between $1.13-$1.28 billion. The company expanded through strategic acquisitions, including assets from Incyte Diagnostics and BioReference Health, while launching innovative oncology tests and expanding its consumer offerings.
The company maintained its shareholder returns with a $0.72 quarterly dividend and $200 million in share repurchases during Q2.
Community Health Systems (NYSE:CYH) has entered into a definitive agreement to sell select ambulatory outreach laboratory assets to Labcorp (NYSE:LH) for $195 million in cash. The transaction covers laboratory services across 13 states, including patient service centers and in-office phlebotomy locations.
CHS will retain operation of inpatient and emergency department laboratories while continuing to provide hospital-based laboratory services. The deal aims to provide broader access to Labcorp's comprehensive testing services, specialty testing menu, data analytics, and digital tools. The transaction is expected to close in Q4 2025, subject to regulatory approvals.
Labcorp (NYSE:LH), a leading global laboratory services provider, has announced a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on September 11, 2025, to shareholders of record as of August 28, 2025.
Labcorp (NYSE:LH), a leading provider of innovative laboratory services, has scheduled its Q2 2025 financial results announcement for July 24, 2025, before market opening. The company will host a conference call and webcast at 9:00 AM ET to discuss the results.
Investors can access the earnings release and financial information on Labcorp's Investor Relations website. A webcast replay will be available approximately two hours after the event until July 11, 2026.